The Institute of Biomedical Research Corp. (OTC PINK:MRES) based in Cape Town, South Africa, is making waves in the nutraceutical biotechnology industry with its innovative approach to plant-based medicines, healthy food products, and sustainable packaging solutions. One of its key divisions, M2Bio Food and Beverage, has recently announced a strategic shift in its product lineup, signaling a new direction for the company.
M2Bio Food and Beverage, known for its premium, healthy, and sustainably sourced products, has decided to discontinue its CBD-infused food products and refocus its efforts on expanding its core offerings. This decision comes in response to the complex scientific and regulatory challenges surrounding CBD in food products. While CBD has shown promise in various health applications, the bioavailability and regulatory uncertainties have posed significant obstacles for the company.
CEO Michael Sachar explains, „We’ve always been committed to innovation, and our exploration of CBD in food products was driven by a desire to tap into its potential benefits. However, the challenges outweigh the benefits in this case. By pivoting away from CBD, we can streamline our operations and focus on delivering high-quality, sustainably sourced foods that our customers trust and love.“
This strategic pivot opens up new opportunities for M2Bio Food and Beverage to enhance its product offerings. The Liviana® product line, known for its premium, organic ingredients, is expected to benefit from this refocus. Without the complexities associated with CBD, the company anticipates broader distribution opportunities, especially in international markets where CBD restrictions have been a barrier.
While stepping back from CBD in food products, M2Bio Food and Beverage remains committed to research and development in the health and wellness sector. The company will continue to explore the therapeutic potential of CBD in topical applications, particularly for pets suffering from skin conditions such as dermatitis.
Jeff Robinson, CEO of M2Bio Sciences, emphasizes the scientific considerations behind this decision, stating, „The challenges of achieving consistent therapeutic outcomes with CBD in food products are significant. By shifting our focus away from CBD-infused foods, we can advance in areas where we can more reliably control and optimize the health benefits of our products.“
As M2Bio Food and Beverage embarks on this new chapter, the company is optimistic about the future. This strategic decision will unlock new growth opportunities, allowing the company to deliver greater value to its customers, partners, and shareholders.
In conclusion, the Institute of Biomedical Research Corp./DBA M2Bio Sciences is at the forefront of bioceutical innovation, focusing on alternative plant-based therapies and mental health therapeutic research. With a commitment to best-practice science and medicine, the company is poised to make a significant impact in the industry. Investors and consumers alike can look forward to the exciting developments coming from M2Bio Food and Beverage in the near future.